analyzeportfolio
OTC · Healthcare

Leef Brands Inc. (LEEEF)

As-reported financials and SEC filings for Leef Brands Inc. The latest annual period is FY2025. The latest reported quarter is Q2 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

Snapshot

Revenue
$34.8M
Revenue growth (YoY)
22.1%
Net income
$-17.6M
Diluted EPS
$-0.10
Gross margin
30.1%
Operating margin
-21.8%
Net margin
-50.7%
FCF margin
-2.8%
ROE
—
net income / fiscal-year-end equity
P/E
n/m
not meaningful: a reported loss in the fiscal year or the trailing twelve months
Market cap
$49.8M
Long-term debt / equity
—
non-current term debt only

Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at Leef Brands

  • Revenue grew 22.1% to $35M in FY2025.
  • Most recent quarter Q2 FY2026: revenue $7M, down 16.3% from Q2 FY2025.
  • Free cash flow was negative $978909 in FY2025.
  • Net loss narrowed to $18M in FY2025, from $25M in FY2024.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where Leef Brands’s fundamentals sit among the 570 Healthcare companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Gross margin30.1%
12th percentile of 290
Operating margin-21.8%
22nd percentile of 410
Net margin-50.7%
10th percentile of 429
FCF margin-2.8%
35th percentile of 385
Revenue growth (YoY)+22.1%
70th percentile of 552
Short interest1.14d
12th percentile of 568

Leef Brands’s net margin of -50.7% ranks in the 10th percentile of the 429 Healthcare companies reporting it. Leef Brands’s gross margin of 30.1% ranks in the 12th percentile of the 290 Healthcare companies reporting it.

No reported insider transactions (codes P/S) in the last 90 days. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
0
code P
Bought (90d)
—
code P value
Sells (90d)
0
—
Reported activity
Quiet
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-06-15
filed 2026-06-16
Kevin John WilsonChief Financial OfficerBuy464.2K$0.23$107K
2026-05-18
filed 2026-10-02
Robert James Mendola Jr.DirectorBuy357.6K$0.25$89K
2026-05-18
filed 2026-05-21
Micah Payne AndersonChief Executive OfficerBuy135.9K$0.25$34K
2026-05-18
filed 2026-05-21
Kevin John WilsonChief Financial OfficerBuy54.3K$0.25$14K

Reported non-derivative purchases and sales (codes P/S), which may be open-market or private. Excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
681.4K
settled 2026-09-30
Change vs prior
+204.7%
vs previous settlement
Days to cover
1.14
at avg daily volume
Avg daily volume
597.4K
FINRA reported
SettlementShares shortChangeDays to cover
2026-09-30681.4K+204.7%1.14
2026-09-15223.6K-53.6%1.00
2026-08-31482.2K+20.1%3.10
2026-08-14401.4K+12.8%1.85
2026-07-31355.7K-45.6%1.00
2026-07-15654.4K-13.1%1.00
2026-06-30752.7K+25.5%1.15
2026-06-15599.7K+16.7%1.00

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2025FY2024
Revenue$34.8M$28.5M
Gross profit
Operating income$-7.6M$-8.0M
Net income$-17.6M$-24.6M
Diluted EPS$-0.10$-0.17

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.

Balance sheet (as reported)

 FY2025FY2024
Cash and equivalents$2.2M$2.7M
Current assets$8.1M$10.5M
Total assets$36.4M$43.0M
Current liabilities$8.3M$11.4M
Long-term debt——
Total liabilities$44.7M$55.4M
Total equity$-8.3M$-12.4M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2025FY2024
Operating cash flow$-336,895$-1.0M
Capital expenditure$642,014$5.9M
Free cash flow

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.

Quarterly trend

QuarterRevenueRevenue YoYNet incomeDiluted EPS
Q2 FY2026$7.3M-16.3%$-1.3M$-0.01
Q1 FY2026$9.4M-0.2%$-426,253$-0.00
Q2 FY2025$8.7M—$-2.9M$-0.02
Q1 FY2025$9.4M—$265,776$0.00

Latest 4 quarters, from company XBRL filings on SEC EDGAR. Revenue YoY is our calculation: each quarter against the same quarter a year earlier.

Company facts

ExchangeOTC
SectorHealthcare
SIC industryMedicinal Chemicals & Botanical Products
Latest annual periodFY2025 (ended December 31, 2025)
Latest reported quarterQ2 FY2026 (ended June 30, 2026)
Oldest indexed filing2017
SEC CIK1711141

Selected SEC filings

10-K2026-03-26
View on EDGAR →
10-Q2026-08-06
View on EDGAR →
10-Q2026-05-06
View on EDGAR →
8-K2026-10-02
View on EDGAR →
8-K2026-08-03
View on EDGAR →
8-K2026-06-02
View on EDGAR →
8-K2026-05-05
View on EDGAR →

Largest Healthcare peers

All Healthcare companies →

Monitor LEEEF

Get an alert when Leef Brands files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor LEEEF free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.